Skip to Main Content
Table 2

Combined effect of CYP17 and HSD17B1 high-risk alleles on breast cancer riska startified by stage and by HRT status

Number of high-risk allelesbP (trend)
01234
Controls (n = 508) 139 435 558 323 53  
Stage 1 cases (n = 615) 52 176 233 134 20  
RRc 1.00 1.12 1.13 1.11 .97  
95% CI  (0.77–1.63) (0.79–1.63) (0.75–1.64) (0.52–1.81) 0.89 
Advanced cases (n = 235) 15 62 87 58 13  
RRd 1.00 1.33 1.42 1.67 2.21  
95% CI  (0.73–2.41) (0.79–2.54) (0.91–3.05) (0.98–5.00) 0.03 
Former and never HRT users       
Controls (n = 1025) 90 298 379 222 36  
Advanced cases (n = 147) 40 55 34  
RRd 1.00 1.36 1.47 1.58 2.60  
95% CI  (0.63–2.92) (0.70–3.09) (0.72–3.43) (0.95–7.14) 0.09 
Current HRT users       
Controls (n = 434) 45 114 166 92 17  
Advanced cases (n = 82) 22 31 21  
RRd 1.00 1.48 1.43 1.77 0.81  
95% CI  (0.56–3.93) (0.56–3.69) (0.66–4.75) (0.15–4.46) 0.58 
Number of high-risk allelesbP (trend)
01234
Controls (n = 508) 139 435 558 323 53  
Stage 1 cases (n = 615) 52 176 233 134 20  
RRc 1.00 1.12 1.13 1.11 .97  
95% CI  (0.77–1.63) (0.79–1.63) (0.75–1.64) (0.52–1.81) 0.89 
Advanced cases (n = 235) 15 62 87 58 13  
RRd 1.00 1.33 1.42 1.67 2.21  
95% CI  (0.73–2.41) (0.79–2.54) (0.91–3.05) (0.98–5.00) 0.03 
Former and never HRT users       
Controls (n = 1025) 90 298 379 222 36  
Advanced cases (n = 147) 40 55 34  
RRd 1.00 1.36 1.47 1.58 2.60  
95% CI  (0.63–2.92) (0.70–3.09) (0.72–3.43) (0.95–7.14) 0.09 
Current HRT users       
Controls (n = 434) 45 114 166 92 17  
Advanced cases (n = 82) 22 31 21  
RRd 1.00 1.48 1.43 1.77 0.81  
95% CI  (0.56–3.93) (0.56–3.69) (0.66–4.75) (0.15–4.46) 0.58 
a

Age, weight, and ethnicity adjusted.

b

High risk alleles: CYP17, A2;HSD17B1, A.

c

Relative risk for stage 1 breast cancer.

d

Relative risk for advanced breast cancer.

Close Modal

or Create an Account

Close Modal
Close Modal